Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: Association to tumor derived alpha-N-acetylgalactosaminidase activity

Cancer Letters

Volumn 283, Issue 2, 2009, Pages 222-229

  Greco, Marilena ^a   Mitri, Marianna De ^b   Chiriacò, Fernanda ^b   Leo, Giuseppe ^a   Brienza, Ettore ^a   Maffia, Michele ^a,b  

^a VITO FAZZI HOSPITAL   (Italy)

^b UNIVERSITY OF SALENTO   (Italy)

Author keywords

Alpha N acetylgalactosaminidase; MALDI TOF; Melanoma; Serum proteomics; Two dimensional electrophoresis

Indexed keywords

ALPHA N ACETYLGALACTOSAMINIDASE; ANGIOTENSINOGEN; PREALBUMIN; VITAMIN D BINDING PROTEIN; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DEGLYCOSYLATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; MELANOMA; NON INVASIVE MEASUREMENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SKIN SURGERY; TUMOR IMMUNITY; BLOOD; DISEASE COURSE; ENZYMOLOGY; MASS SPECTROMETRY; PATHOLOGY; SKIN TUMOR; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ALPHA-N-ACETYLGALACTOSAMINIDASE; DISEASE PROGRESSION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MELANOMA; NEOPLASM STAGING; PROTEOMICS; SKIN NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 69849104251     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.04.001     Document Type: Article

References (37)

1. Gray-Schopfer V., Wellbrock C., and Marais R. Melanoma biology and new targeted therapy. Nature 445 (2007) 851-857
2. Cummins D.L., Cummins J.M., Pantle H., Silverman M.A., Leonard A.L., and Chanmugam A. Cutaneous malignant melanoma. Mayo Clin. Proc. 81 (2006) 500-507
3. Mian S., Ugurel S., Parkinson E., Schlenzka I., Dryden I., Lancashire L., et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J. Clin. Oncol. 23 (2005) 5088-5093
4. Appel R.D., and Hochstrasser D.F. Computer analysis of 2-D images. Methods Mol. Biol. 112 (1999) 363-381
5. Candiano G., Bruschi M., Musante L., Santucci L., et al. Blue silver: a very sensitive colloidal coomassie G-250 staining for proteome analysis. Electrophoresis 25 (2004) 1327-1333
6. Liebl W., Wagner B., and Schellhase J. Properties of an alpha-galactosidase, and structure of its gene galA, within an alpha- and beta-galactoside utilization gene cluster of the hyperthermophilic bacterium Thermotoga maritime. Syst. Appl. Microbiol. 21 (1998) 1-11
7. Gomme P.T., and Bertolini J. Therapeutic potential of vitamin D-binding protein. Trends Biotechnol. 22 (2004) 340-345
8. Koga Y., Naraparaju V.R., and Yamamoto N. Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing mice. Proc. Soc. Exp. Biol. Med. 220 (1999) 20-26
9. Yamamoto N., and Naraparaju V.R. Role of vitamin D3-binding protein in activation of mouse macrophages. J. Immunol. 157 (1996) 1744-1749
10. Yamamoto N., Naraparaju V.R., and Asbell S.O. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res. 56 (1996) 2827-2831
11. Mohamad S.B., Nagasawa H., Uto Y., and Hori H. Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 132 (2002) 1-8
12. Mohamad S.B., Nagasawa H., Uto Y., and Hori H. Preparation of Gc protein-derived macrophage activating factor (GcMAF) and its structural characterization and biological activities. Anticancer Res. 22 (2002) 4297-4300
13. Ruano D., Macedo A., Soares M.J., Valente J., Azevedo M.H., Hutz M.H., et al. Transthyret: no association between serum levels or gene variants and schizophrenia. J. Psychiatr. Res. 41 (2007) 667-672
14. Gaetani S., Bellovino D., Apreda M., and Devirgiliis C. Hepatic synthesis, maturation and complex formation between retinol-binding protein and transthyretin. Clin. Chem. Lab. Med. 40 (2002) 1211-1220
15. Monaco H.L. The transthyretin-retinol-binding protein complex. Biochim. Biophys. Acta 1482 (2000) 65-72
16. Niles R.M., and Combs R. The relationship between susceptibility to retinoic acid treatment and protein kinase C alpha expression in murine melanoma cell lines. Exp. Cell. Res. 223 (1996) 20-28
17. Chandraratna R.A. Future trends: a new generation of retinoids. J. Am. Acad. Dermatol. 39 (1998) S149-152
18. Fernandes S.S., Arcuri R., Morgado-Diaz J.A., and Benchimol M. Increase of melanogenesis by retinoic acid: an ultra structural and morphometric study. Tissue Cell 36 (2004) 95-105
19. Naylor H.M., and Newcomer M.E. The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. Biochemistry 38 (1999) 2647-2653
20. Simmons D.P., Andreola F., and De Luca L.M. Human melanomas of fibroblast and epithelial morphology differ widely in their ability to synthesize retinyl esters. Carcinogenesis 23 (2002) 1821-1830
21. Bouquet C., Lamande N., Gasc J.M., Griscelli F., Opolon P., Connault E., et al. Angiotensinogen inhibits growth and angiogenesis of human mammary carcinoma and prevents pulmonary metastasis of murine melanoma cancer. Mol. Ther. 9 (2004) S370
22. Bouquet C., Lamande N., Brand M., Gasc J.M., Jullienne B., Faure G., et al. Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen. Mol. Ther. 14 (2006) 175-182
23. Greco M., Chiriacò F., Del Boccio P., Tagliaferro L., et al. A proteomic approach in the characterization of the C677T mutation of the HUMAN gene methylen tetrahydrofolate reductase (MTHFR). Proteomics 6 (2006) 5350-5361
24. Yamamoto N., Naraparaju V.R., and Urade M. Prognostic utility of serum α-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients. Cancer Res. 57 (1997) 295-299
25. Yamamoto N., and Naraparaju V.R. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res. 57 (1997) 2187-2192
26. Yamamoto N., Suyama H., Yamamoto N.Y., and Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein derived macrophage activating factor (GcMAF). Int. J. Cancer 122 (2008) 461-467
27. Yamamoto N., Suyama H., and Yamamoto N. Immunotherapy for prostate cancer with gc protein-derived macrophage-activating factor, GcMAF. Translational Oncol. 1 (2008) 65-72
28. Yamamoto N., Suyama H., Nakazato H., Yamamoto N., and Koga Y. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol. Immunother. 57 (2008) 1007-1016
29. Kanda S., Mochizuki Y., Miyata Y., Kanetake H., and Yamamoto N. Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. J. Natl. Cancer Inst. 94 (2002) 1311-1319
30. Feng J.T., Liu Y.K., Song H.Y., Dai Z., Qin L.X., Almofti M.R., et al. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 5 (2005) 4581-4588
31. Juan H.F., Chen J.H., Hsu W.T., Huang S.C., Chen S.T., Yi-Chung Lin J., et al. Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics 4 (2004) 2766-2775
32. Sun Z.L., Zhu Y., Wang F.Q., Chen R., Peng T., Fan Z.N., et al. Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers. Biochim. Biophys. Acta 1774 (2007) 764-771
33. Koomen J.M., Zhao H., Li D., Nasser W., Hawke D.H., Abbruzzese J.L., et al. Diagnostic protein discovery using liquid chromatography/mass spectrometry for proteolytic peptide targeting. Rapid Commun. Mass Spectrom. 19 (2005) 1624-1636
34. Koomen J.M., Shih L.N., Coombes K.R., Li D., Xiao L.C., Fidler I.J., et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin. Cancer Res. 11 (2005) 1110-1118
35. Zhao C., Annamalai L., Guo C., Kothandaraman N., Koh S.C., Zhang H., et al. Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia 9 (2007) 1-7
36. Liu W., Liu B., Xin L., Zhang Y., Chen X., Zhu Z., et al. Down-regulated expression of complement factor I: a potential suppressive protein for gastric cancer identified by serum proteome analysis. Clin. Chim. Acta 377 (2007) 119-126
37. Kuraya M., Ming Z., Liu X., Matsushita M., and Fujita T. Specific binding of L-ficolin and H-ficolin to apoptotic cells leads to complement activation. Immunobiology 209 (2005) 689-697